000285454 001__ 285454
000285454 005__ 20260305131033.0
000285454 0247_ $$2doi$$a10.3389/fpsyt.2026.1735191
000285454 0247_ $$2pmid$$apmid:41767150
000285454 0247_ $$2pmc$$apmc:PMC12946022
000285454 037__ $$aDZNE-2026-00236
000285454 041__ $$aEnglish
000285454 082__ $$a610
000285454 1001_ $$aSchulze, Marcel$$b0
000285454 245__ $$aQuantitative susceptibility mapping of brain iron in adult ADHD.
000285454 260__ $$aLausanne$$bFrontiers Research Foundation$$c2026
000285454 3367_ $$2DRIVER$$aarticle
000285454 3367_ $$2DataCite$$aOutput Types/Journal article
000285454 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772710780_14049
000285454 3367_ $$2BibTeX$$aARTICLE
000285454 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285454 3367_ $$00$$2EndNote$$aJournal Article
000285454 520__ $$aAttention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that frequently persists into adulthood and is linked to alterations in fronto-striatal circuitry and dopaminergic signaling. Brain iron is essential for dopamine synthesis and neural metabolism and can be indexed in vivo using quantitative susceptibility mapping (QSM), which reflects regional magnetic susceptibility. Pediatric studies have mostly reported reduced tissue iron susceptibility in ADHD, but data in adults are limited. This study investigated regional susceptibility in adults with ADHD, its relationship to current and retrospective ADHD symptoms, and depression.Twenty-five adults with ADHD and 24 healthy controls underwent 3T MRI, including high-resolution QSM. Mean susceptibility was extracted from 89 cortical and subcortical regions of interest. For each ROI, group effects were estimated using linear regression with heteroskedasticity-consistent (HC3) inference. To account for group differences in depressive symptoms, additional models included Beck Depression Inventory (BDI-II) scores. Dimensional associations with ADHD symptoms were tested using covariate-adjusted ROI-symptom correlations for current symptoms (CAARS) and retrospective childhood symptoms (WURS-k). Benjamini-Hochberg false discovery rate (FDR) correction was applied within each analysis across ROIs.No ADHD-control group difference survived FDR correction in any model. At the uncorrected level, adults with ADHD showed lower susceptibility in ventral temporal and posterior midline regions, most consistently in the fusiform gyrus and posterior cingulate cortex (small-to-moderate effect sizes across models). When additionally adjusting for depressive symptoms, nominal group differences remained confined to ventral temporal/temporo-limbic and orbitofrontal regions (fusiform, entorhinal cortex, medial orbitofrontal cortex), but again did not survive FDR. Covariate-adjusted ROI-symptom associations did not meet FDR significance; nominally, higher ADHD symptom burden (particularly impulsivity) was associated with lower susceptibility in posterior midline regions (posterior cingulate, precuneus) and ventral temporal cortex (fusiform).In this adult sample, QSM provided no robust evidence for widespread or regionally specific alterations in brain iron susceptibility in ADHD after multiple-comparison correction. Nevertheless, the reproducible pattern of nominal effects-centered on ventral temporal and default-mode network hub regions-suggests that inter-individual variation in cortical susceptibility may relate to clinical heterogeneity and neurodevelopmental timing rather than constituting a strong diagnostic signature. Larger, medication-stratified and developmentally informed studies are needed to clarify whether subtle iron-related susceptibility patterns track symptom dimensions, treatment exposure, and longitudinal trajectories.
000285454 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000285454 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285454 650_7 $$2Other$$aADHD
000285454 650_7 $$2Other$$aQSM
000285454 650_7 $$2Other$$abrain iron
000285454 650_7 $$2Other$$aneurodevelopment
000285454 650_7 $$2Other$$asymptom-coupling
000285454 7001_ $$aAutenrieth, Erik$$b1
000285454 7001_ $$aAslan, Behrem$$b2
000285454 7001_ $$0P:(DE-2719)2810697$$aStirnberg, Rüdiger$$b3$$udzne
000285454 7001_ $$0P:(DE-2719)2810538$$aStoecker, Tony$$b4$$udzne
000285454 7001_ $$aLux, Silke$$b5
000285454 7001_ $$aCoghill, David$$b6
000285454 7001_ $$aSilk, Tim$$b7
000285454 7001_ $$aPhilipsen, Alexandra$$b8
000285454 773__ $$0PERI:(DE-600)2564218-2$$a10.3389/fpsyt.2026.1735191$$gVol. 17, p. 1735191$$p1735191$$tFrontiers in psychiatry$$v17$$x1664-0640$$y2026
000285454 8564_ $$uhttps://pub.dzne.de/record/285454/files/DZNE-2026-00236%20SUP.pdf
000285454 8564_ $$uhttps://pub.dzne.de/record/285454/files/DZNE-2026-00236%20SUP.pdf?subformat=pdfa$$xpdfa
000285454 8564_ $$uhttps://pub.dzne.de/record/285454/files/DZNE-2026-00236.pdf$$yRestricted
000285454 8564_ $$uhttps://pub.dzne.de/record/285454/files/DZNE-2026-00236.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285454 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810697$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285454 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810538$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285454 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000285454 9141_ $$y2026
000285454 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT PSYCHIATRY : 2022$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-05-13T11:24:59Z
000285454 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-05-13T11:24:59Z
000285454 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-05-13T11:24:59Z
000285454 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2025-05-13T11:24:59Z
000285454 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-05
000285454 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-05
000285454 9201_ $$0I:(DE-2719)1013026$$kAG Stöcker$$lMR Physics$$x0
000285454 980__ $$ajournal
000285454 980__ $$aVDB
000285454 980__ $$aI:(DE-2719)1013026
000285454 980__ $$aUNRESTRICTED